3-Hydroxymethyl-1-methyl-hexahydroazepin | 50585-85-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 3-Hydroxymethyl-1-methyl-hexahydroazepin
• 英文别名: (1-Methylazepan-3-yl)methanol
• CAS: 50585-85-8
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: SJJXIAHKOZPIDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Amidobenzamide derivatives which are useful as cytokine inhibitors
  申请人：Brown S. Dearg

  公开号：US20050038081A1

  公开（公告）日：2005-02-17

  The invention concerns amide derivatives of the Formula (I) wherein R 3 is (1-6C)alkyl or halogeno; Q is aryl or heteroaryl which optionally bears 1, 2, 3 or 4 substituents such as hydroxy, halogeno, trifluoromethyl, cyano, (1-6C)alkyl, (1-6C)alkoxy, halogeno-(1-6C)alkyl, hydroxyl-(1-6C)alkyl, di-[(1-6C)akly]amino-(1-6C)alkyl, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, aryl, aryl-(1-6C)alkoxy, heteroaryl, heteroaryl-(1-6C)alkoxy, heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy and heterocyclyl-(1-6C)alkoxy; p is 0-2 and R 2 is a substituent such as hydroxy and halogeno; q is 0-4; and R 4 includes optionally substituted aryl, cycloalkyl, heteroaryl and heterocyclyl; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及公式（I）的酰胺衍生物，其中R3是（1-6C）烷基或卤素基; Q是芳基或杂环芳基，其可选地带有1、2、3或4个取代基，例如羟基、卤素基、三氟甲基、氰基、（1-6C）烷基、（1-6C）烷氧基、卤代（1-6C）烷基、羟基（1-6C）烷基、二-[(1-6C)烷基]氨基（1-6C）烷基、羟基（2-6C）烷氧基、（1-6C）烷氧基（2-6C）烷氧基、二-[(1-6C)烷基]氨基（2-6C）烷氧基、氨基（2-6C）烷基氨基、N-(1-6C)烷基-(1-6C)烷基氨基-(2-6C)烷基氨基、芳基、芳基-(1-6C)烷氧基、杂环芳基、杂环芳基-(1-6C)烷氧基、杂环基、杂环基-(1-6C)烷基、杂环氧基和杂环基-(1-6C)烷氧基; p为0-2，R2是羟基和卤素基等取代基; q为0-4; R4包括可选的取代芳基、环烷基、杂环芳基和杂环基; 或其药学上可接受的盐或体内可水解的酯; 以及制备它们的方法、包含它们的制药组合物以及它们在治疗由细胞因子介导的疾病或医疗条件中的用途。
• AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
  申请人：Novira Therapeutics, Inc.

  公开号：US20150197533A1

  公开（公告）日：2015-07-16

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

  本文提供了一些化合物，用于治疗需要治疗乙型肝炎感染的患者，以及这些化合物的药物组合物和抑制、抑制或预防患者乙型肝炎感染的方法。
• Azepane derivatives and methods of treating hepatitis B infections
  申请人：Novira Therapeutics, Inc.

  公开号：US10392349B2

  公开（公告）日：2019-08-27

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

  本文提供了用于治疗有需要的受试者 HBV 感染的化合物、其药物组合物以及抑制、抑制或预防受试者 HBV 感染的方法。
• AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS
  申请人：AstraZeneca AB

  公开号：EP1102743B1

  公开（公告）日：2002-07-24
• AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
  申请人：Novira Therapeutics, Inc.

  公开号：US20170015629A1

  公开（公告）日：2017-01-19

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.